{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:58:55Z","timestamp":1794355135949,"version":"4.9.0"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000135","name":"NIH Blueprint for Neuroscience Research","doi-asserted-by":"publisher","award":["R01AI050875"],"award-info":[{"award-number":["R01AI050875"]}],"id":[{"id":"10.13039\/100000135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000135","name":"NIH Blueprint for Neuroscience Research","doi-asserted-by":"publisher","award":["R21AI121700"],"award-info":[{"award-number":["R21AI121700"]}],"id":[{"id":"10.13039\/100000135","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00018-023-04729-4","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T04:02:36Z","timestamp":1679457756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":143,"title":["Receptor tyrosine kinase inhibitors in cancer"],"prefix":"10.1007","volume":"80","author":[{"given":"Nasim","family":"Ebrahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmira","family":"Fardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajarossadat","family":"Ghaderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Palizdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Khorram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Vafadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Ghanaatian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Rezaei-Tazangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Baziyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Reza","family":"Aref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"4729_CR1","unstructured":"Cancer [Internet]. World Health Organization (2022). Available from https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer"},{"issue":"4","key":"4729_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A et al (2021) Cancer statistics for the year 2020: an overview. Int J Cancer 149(4):778\u2013789","journal-title":"Int J Cancer"},{"issue":"2","key":"4729_CR3","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","volume":"8","author":"C de Martel","year":"2020","unstructured":"de Martel C, Georges D, Bray F, Ferlay J, Clifford GM (2020) Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 8(2):e180\u2013e190","journal-title":"Lancet Glob Health"},{"key":"4729_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.772510","volume":"12","author":"S Sudhesh Dev","year":"2021","unstructured":"Sudhesh Dev S, Zainal Abidin SA, Farghadani R, Othman I, Naidu R (2021) Receptor tyrosine kinases and their signaling pathways as therapeutic targets of curcumin in cancer. Front Pharmacol 12:772510","journal-title":"Front Pharmacol"},{"key":"4729_CR5","doi-asserted-by":"publisher","first-page":"106041","DOI":"10.1016\/j.phrs.2021.106041","volume":"176","author":"SA Miraghel","year":"2021","unstructured":"Miraghel SA, Ebrahimi N, Khani L, Mansouri A, Jafarzadeh A, Ahmadi A et al (2021) Crosstalk between non-coding RNAs expression profile, drug resistance and immune response in breast cancer. Pharmacol Res 176:106041","journal-title":"Pharmacol Res"},{"issue":"9","key":"4729_CR6","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1111\/bph.13450","volume":"173","author":"S Carvalho","year":"2016","unstructured":"Carvalho S, Levi-Schaffer F, Sela M, Yarden Y (2016) Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR review 18. Br J Pharmacol 173(9):1407\u20131424","journal-title":"Br J Pharmacol"},{"issue":"12","key":"4729_CR7","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3390\/biomedicines9121798","volume":"9","author":"EDG Fleuren","year":"2021","unstructured":"Fleuren EDG, Terry RL, Meyran D, Omer N, Trapani JA, Haber M et al (2021) Enhancing the potential of immunotherapy in paediatric sarcomas: breaking the immunosuppressive barrier with receptor tyrosine kinase inhibitors. Biomedicines. 9(12):1798","journal-title":"Biomedicines."},{"issue":"10","key":"4729_CR8","doi-asserted-by":"publisher","first-page":"17313","DOI":"10.18632\/oncotarget.14388","volume":"8","author":"KG Liu","year":"2017","unstructured":"Liu KG, Gupta S, Goel S (2017) Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. Oncotarget 8(10):17313\u201317327","journal-title":"Oncotarget"},{"issue":"2","key":"4729_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3390\/ijms18020383","volume":"18","author":"C Abou-Fay\u00e7al","year":"2017","unstructured":"Abou-Fay\u00e7al C, Hatat AS, Gazzeri S, Eymin B (2017) Splice variants of the RTK family: their role in tumour progression and response to targeted therapy. Int J Mol Sci 18(2):383","journal-title":"Int J Mol Sci"},{"key":"4729_CR10","volume-title":"Physiology, tyrosine kinase receptors. StatPearls","author":"GA Wintheiser","year":"2022","unstructured":"Wintheiser GA, Silberstein P (2022) Physiology, tyrosine kinase receptors. StatPearls. StatPearls Publishing LLC., Treasure Island (FL)"},{"key":"4729_CR11","volume-title":"Tyrosine kinase inhibitor keratitis. StatPearls","author":"M Moshirfar","year":"2022","unstructured":"Moshirfar M, Villarreal A, Ronquillo Y (2022) Tyrosine kinase inhibitor keratitis. StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"issue":"2","key":"4729_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7150\/ijms.1.101","volume":"1","author":"MK Paul","year":"2004","unstructured":"Paul MK, Mukhopadhyay AK (2004) Tyrosine kinase\u2013role and significance in cancer. Int J Med Sci 1(2):101","journal-title":"Int J Med Sci"},{"issue":"5","key":"4729_CR13","doi-asserted-by":"publisher","first-page":"E973","DOI":"10.1152\/ajpendo.90857.2008","volume":"296","author":"JV Abella","year":"2009","unstructured":"Abella JV, Park M (2009) Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endocrinol Metab 296(5):E973\u2013E984","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4729_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.680834","volume":"11","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zhang D, Guo Y, Lu B, Zhao ZJ, Xu X et al (2021) Tyrosine kinase ROR1 as a target for anti-cancer therapies. Front Oncol 11:680834","journal-title":"Front Oncol"},{"issue":"18","key":"4729_CR15","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1093\/emboj\/16.18.5572","volume":"16","author":"SR Hubbard","year":"1997","unstructured":"Hubbard SR (1997) Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16(18):5572\u20135581","journal-title":"EMBO J"},{"issue":"4","key":"4729_CR16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3934\/biophy.2015.4.476","volume":"2","author":"OA Karpov","year":"2015","unstructured":"Karpov OA, Fearnly GW, Smith GA, Kankanala J, McPherson MJ, Tomlinson DC et al (2015) Receptor tyrosine kinase structure and function in health and disease. AIMS Biophys. 2(4):476\u2013502","journal-title":"AIMS Biophys."},{"issue":"1","key":"4729_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2015.01.001","volume":"4","author":"AI S\u00e9galiny","year":"2015","unstructured":"S\u00e9galiny AI, Tellez-Gabriel M, Heymann MF, Heymann D (2015) Receptor tyrosine kinases: characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol 4(1):1\u201312","journal-title":"J Bone Oncol"},{"issue":"1","key":"4729_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du Z, Lovly CM (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17(1):58","journal-title":"Mol Cancer"},{"issue":"7","key":"4729_CR19","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1073\/pnas.93.7.2729","volume":"93","author":"JP O'Bryan","year":"1996","unstructured":"O\u2019Bryan JP, Songyang Z, Cantley L, Der CJ, Pawson T (1996) A mammalian adaptor protein with conserved Src homology 2 and phosphotyrosine-binding domains is related to Shc and is specifically expressed in the brain. Proc Natl Acad Sci USA 93(7):2729\u20132734","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"4729_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"141","author":"MA Lemmon","year":"2010","unstructured":"Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141(7):1117\u20131134","journal-title":"Cell"},{"issue":"2","key":"4729_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11684-015-0396-9","volume":"9","author":"PB Alexander","year":"2015","unstructured":"Alexander PB, Wang XF (2015) Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies. Front Med 9(2):134\u2013138","journal-title":"Front Med"},{"issue":"2","key":"4729_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3390\/cells3020304","volume":"3","author":"IN Maruyama","year":"2014","unstructured":"Maruyama IN (2014) Mechanisms of activation of receptor tyrosine kinases: monomers or dimers. Cells 3(2):304\u2013330","journal-title":"Cells"},{"key":"4729_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12195-013-0303-x","volume":"7","author":"C Monast","year":"2013","unstructured":"Monast C, Mehta N, Lazzara M (2013) Diversity in dimerization topologies enables differential control of receptor tyrosine kinase phosphorylation dynamics. Cell Mol Bioeng. 7:86","journal-title":"Cell Mol Bioeng."},{"issue":"5","key":"4729_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","volume":"15","author":"B Nolen","year":"2004","unstructured":"Nolen B, Taylor S, Ghosh G (2004) Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 15(5):661\u2013675","journal-title":"Mol Cell"},{"issue":"35","key":"4729_CR25","doi-asserted-by":"publisher","first-page":"31768","DOI":"10.1074\/jbc.M203995200","volume":"277","author":"XL Niu","year":"2002","unstructured":"Niu XL, Peters KG, Kontos CD (2002) Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function. Evidence for an autoinhibitory mechanism. J Biol Chem 277(35):31768\u201331773","journal-title":"J Biol Chem"},{"issue":"9","key":"4729_CR26","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrc1434","volume":"4","author":"NJ Dibb","year":"2004","unstructured":"Dibb NJ, Dilworth SM, Mol CD (2004) Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 4(9):718\u2013727","journal-title":"Nat Rev Cancer"},{"issue":"44","key":"4729_CR27","doi-asserted-by":"publisher","first-page":"33577","DOI":"10.1074\/jbc.M605604200","volume":"281","author":"PP Knowles","year":"2006","unstructured":"Knowles PP, Murray-Rust J, Kj\u00e6r S, Scott RP, Hanrahan S, Santoro M et al (2006) Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281(44):33577\u201333587","journal-title":"J Biol Chem"},{"issue":"6","key":"4729_CR28","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.cell.2006.05.013","volume":"125","author":"X Zhang","year":"2006","unstructured":"Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125(6):1137\u20131149","journal-title":"Cell"},{"issue":"12","key":"4729_CR29","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2(12):1097\u20131105","journal-title":"Genes Cancer"},{"issue":"6","key":"4729_CR30","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/j.1349-7006.2009.01143.x","volume":"100","author":"H Futami","year":"2009","unstructured":"Futami H, Sakai R (2009) RET protein promotes non-adherent growth of NB-39-nu neuroblastoma cell line. Cancer Sci 100(6):1034\u20131039","journal-title":"Cancer Sci"},{"issue":"4","key":"4729_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4161\/org.5.4.10048","volume":"5","author":"S Jain","year":"2009","unstructured":"Jain S (2009) The many faces of RET dysfunction in kidney. Organogenesis 5(4):177\u2013190","journal-title":"Organogenesis"},{"issue":"7","key":"4729_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/jmg.2010.088526","volume":"48","author":"C Jeanpierre","year":"2011","unstructured":"Jeanpierre C, Mac\u00e9 G, Parisot M, Morini\u00e8re V, Pawtowsky A, Benabou M et al (2011) RET and GDNF mutations are rare in fetuses with renal agenesis or other severe kidney development defects. J Med Genet 48(7):497\u2013504","journal-title":"J Med Genet"},{"key":"4729_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134676","volume":"716","author":"R Herbst","year":"2020","unstructured":"Herbst R (2020) MuSK function during health and disease. Neurosci Lett 716:134676","journal-title":"Neurosci Lett"},{"issue":"1","key":"4729_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12943-019-1022-2","volume":"18","author":"KV Myers","year":"2019","unstructured":"Myers KV, Amend SR, Pienta KJ (2019) Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Mol Cancer 18(1):94","journal-title":"Mol Cancer"},{"key":"4729_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pharmthera.2018.03.002","volume":"188","author":"B Shafit-Zagardo","year":"2018","unstructured":"Shafit-Zagardo B, Gruber RC, DuBois JC (2018) The role of TAM family receptors and ligands in the nervous system: From development to pathobiology. Pharmacol Ther 188:97\u2013117","journal-title":"Pharmacol Ther"},{"issue":"20","key":"4729_CR36","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1042\/BCJ20200695","volume":"477","author":"SC Artim","year":"2020","unstructured":"Artim SC, Kiyatkin A, Lemmon MA (2020) Comparison of tyrosine kinase domain properties for the neurotrophin receptors TrkA and TrkB. Biochem J 477(20):4053\u20134070","journal-title":"Biochem J"},{"key":"4729_CR37","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cancergen.2022.01.003","volume":"262\u2013263","author":"SS Lang","year":"2022","unstructured":"Lang SS, Kumar NK, Madsen P, Gajjar AA, Gajjar E, Resnick AC et al (2022) Neurotrophic tyrosine receptor kinase fusion in pediatric central nervous system tumors. Cancer Genet 262\u2013263:64\u201370","journal-title":"Cancer Genet"},{"issue":"22","key":"4729_CR38","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.3390\/cancers13225639","volume":"13","author":"D Yan","year":"2021","unstructured":"Yan D, Earp HS, DeRyckere D, Graham DK (2021) Targeting MERTK and AXL in EGFR mutant non-small cell lung cancer. Cancers 13(22):5639","journal-title":"Cancers"},{"issue":"7","key":"4729_CR39","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/cancers13071521","volume":"13","author":"M Wium","year":"2021","unstructured":"Wium M, Ajayi-Smith AF, Paccez JD, Zerbini LF (2021) The role of the receptor tyrosine kinase Axl in carcinogenesis and development of therapeutic resistance: an overview of molecular mechanisms and future applications. Cancers 13(7):1521","journal-title":"Cancers"},{"issue":"4","key":"4729_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jgg.2021.02.011","volume":"48","author":"P Zhao","year":"2021","unstructured":"Zhao P, Jiang D, Huang Y, Chen C (2021) EphA2: a promising therapeutic target in breast cancer. J Genet Genomics Yi chuan xue bao 48(4):261\u2013267","journal-title":"J Genet Genomics Yi chuan xue bao"},{"key":"4729_CR41","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.21032","volume":"5","author":"M Chu","year":"2016","unstructured":"Chu M, Li T, Shen B, Cao X, Zhong H, Zhang L et al (2016) Angiopoietin receptor Tie2 is required for vein specification and maintenance via regulating COUP-TFII. Elife 5:e21032","journal-title":"Elife"},{"issue":"10","key":"4729_CR42","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00018-008-7440-8","volume":"65","author":"M Wieduwilt","year":"2008","unstructured":"Wieduwilt M, Moasser M (2008) The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 65(10):1566\u20131584","journal-title":"Cell Mol Life Sci"},{"key":"4729_CR43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-immunol-032414-112103","volume":"33","author":"CV Rothlin","year":"2015","unstructured":"Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S (2015) TAM receptor signaling in immune homeostasis. Annu Rev Immunol 33:355\u2013391","journal-title":"Annu Rev Immunol"},{"key":"4729_CR44","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.brainres.2013.10.049","volume":"1542","author":"AM Pierce","year":"2014","unstructured":"Pierce AM, Keating AK (2014) TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central nervous system. Brain Res 1542:206\u2013220","journal-title":"Brain Res"},{"issue":"5","key":"4729_CR45","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009167","volume":"5","author":"SJ Burden","year":"2013","unstructured":"Burden SJ, Yumoto N, Zhang W (2013) The role of MuSK in synapse formation and neuromuscular disease. Cold Spring Harb Perspect Biol 5(5):a009167","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"4729_CR46","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-1-4939-1789-1_16","volume":"1233","author":"C Corcoran","year":"2015","unstructured":"Corcoran C, O\u2019Driscoll L (2015) Receptor tyrosine kinases and drug resistance: development and characterization of in vitro models of resistance to RTK inhibitors. Methods Mol Biol (Clifton, NJ) 1233:169\u2013180","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"issue":"2","key":"4729_CR47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1055-3207(18)30065-6","volume":"10","author":"L Lamorte","year":"2001","unstructured":"Lamorte L, Park M (2001) The receptor tyrosine kinases: role in cancer progression. Surg Oncol Clin N Am 10(2):271\u2013288","journal-title":"Surg Oncol Clin N Am"},{"issue":"4","key":"4729_CR48","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2174\/1573409912666151124233847","volume":"11","author":"P Sharma","year":"2015","unstructured":"Sharma P, Shukla A, Kalani K, Dubey V, Srivastava SK, Luqman S et al (2015) Water molecules increases binding affinity of natural PI3K\u03b3 inhibitors against cancer. Curr Comput Aided Drug Des 11(4):304\u2013320","journal-title":"Curr Comput Aided Drug Des"},{"issue":"3","key":"4729_CR49","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169\u2013181","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"4729_CR50","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1248\/bpb.34.1774","volume":"34","author":"K Takeuchi","year":"2011","unstructured":"Takeuchi K, Ito F (2011) Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 34(12):1774\u20131780","journal-title":"Biol Pharm Bull"},{"issue":"8","key":"4729_CR51","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","volume":"30","author":"K Bergethon","year":"2012","unstructured":"Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol Off J Am Soc Clin Oncol 30(8):863\u2013870","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"4729_CR52","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.clml.2016.06.002","volume":"16","author":"M Hassanein","year":"2016","unstructured":"Hassanein M, Almahayni MH, Ahmed SO, Gaballa S, El Fakih R (2016) FLT3 Inhibitors for Treating Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 16(10):543\u2013549","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"4729_CR53","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R (2017) RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res Off J Am Assoc Cancer Res 23(8):1988\u20131997","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"4729_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12964-019-0486-4","volume":"18","author":"NJ Chew","year":"2020","unstructured":"Chew NJ, Nguyen EV, Su SP, Novy K, Chan HC, Nguyen LK et al (2020) FGFR3 signaling and function in triple negative breast cancer. Cell Commun Signal 18(1):13","journal-title":"Cell Commun Signal"},{"issue":"10","key":"4729_CR55","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1158\/1535-7163.MCT-21-0329","volume":"20","author":"JJ Adashek","year":"2021","unstructured":"Adashek JJ, Desai AP, Andreev-Drakhlin AY, Roszik J, Cote GJ, Subbiah V (2021) Hallmarks of RET and co-occuring genomic alterations in RET-aberrant cancers. Mol Cancer Ther 20(10):1769\u20131776","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"4729_CR56","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/cancers7030860","volume":"7","author":"T Regad","year":"2015","unstructured":"Regad T, Targeting RTK (2015) Signaling pathways in cancer. Cancers 7(3):1758\u20131784","journal-title":"Cancers"},{"issue":"4","key":"4729_CR57","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","volume":"12","author":"M Chevallier","year":"2021","unstructured":"Chevallier M, Borgeaud M, Addeo A, Friedlaender A (2021) Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol 12(4):217\u2013237","journal-title":"World J Clin Oncol"},{"issue":"19","key":"4729_CR58","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.3748\/wjg.v23.i19.3440","volume":"23","author":"WM Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman WM, Al-Khayyal NA, Nair VA, Aravind SR, Saber-Ayad M (2017) Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations. World J Gastroenterol 23(19):3440\u20133448","journal-title":"World J Gastroenterol"},{"issue":"8","key":"4729_CR59","doi-asserted-by":"publisher","first-page":"618","DOI":"10.2174\/138920211798120835","volume":"12","author":"A Taccaliti","year":"2011","unstructured":"Taccaliti A, Silvetti F, Palmonella G, Boscaro M (2011) Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. Curr Genomics 12(8):618\u2013625","journal-title":"Curr Genomics"},{"issue":"3","key":"4729_CR60","first-page":"148","volume":"3","author":"H-N Mo","year":"2017","unstructured":"Mo H-N, Liu P (2017) Targeting MET in cancer therapy. Chronic Dis Transl Med 3(3):148\u2013153","journal-title":"Chronic Dis Transl Med"},{"key":"4729_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731527","volume":"12","author":"S Zhao","year":"2021","unstructured":"Zhao S, Wu W, Jiang H, Ma L, Pan C, Jin C et al (2021) Selective inhibitor of the c-Met receptor tyrosine kinase in advanced hepatocellular carcinoma: no beneficial effect with the use of tivantinib? Front Immunol 12:731527","journal-title":"Front Immunol"},{"issue":"1","key":"4729_CR62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/14656566.2016.1261825","volume":"18","author":"HY Woo","year":"2017","unstructured":"Woo HY, Yoo SY, Heo J (2017) New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails? Expert Opin Pharmacother 18(1):35\u201344","journal-title":"Expert Opin Pharmacother"},{"issue":"18","key":"4729_CR63","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.3748\/wjg.v21.i18.5445","volume":"21","author":"X-S Qi","year":"2015","unstructured":"Qi X-S, Guo X-Z, Han G-H, Li H-Y, Chen J (2015) MET inhibitors for treatment of advanced hepatocellular carcinoma: a review. World J Gastroenterol: WJG 21(18):5445","journal-title":"World J Gastroenterol: WJG"},{"issue":"6","key":"4729_CR64","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrclinonc.2012.71","volume":"9","author":"S Peters","year":"2012","unstructured":"Peters S, Adjei AA (2012) MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 9(6):314\u2013326","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4729_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12964-020-00694-8","volume":"19","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Wang Y, Chen H, Xu Y, Luo Y, Deng Y et al (2021) Immuno-oncology: are TAM receptors in glioblastoma friends or foes? Cell Commun Signal 19(1):11","journal-title":"Cell Commun Signal"},{"key":"4729_CR66","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.2147\/DDDT.S89114","volume":"10","author":"M AbbaspourBabaei","year":"2016","unstructured":"AbbaspourBabaei M, Kamalidehghan B, Saleem M, Huri HZ, Ahmadipour F (2016) Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Dev Ther 10:2443\u20132459","journal-title":"Drug Des Dev Ther"},{"issue":"50","key":"4729_CR67","doi-asserted-by":"publisher","first-page":"31680","DOI":"10.1016\/S0021-9258(18)31749-6","volume":"269","author":"MF Brizzi","year":"1994","unstructured":"Brizzi MF, Zini MG, Aronica MG, Blechman JM, Yarden Y, Pegoraro L (1994) Convergence of signaling by interleukin-3, granulocyte-macrophage colony-stimulating factor, and mast cell growth factor on JAK2 tyrosine kinase. J Biol Chem 269(50):31680\u201331684","journal-title":"J Biol Chem"},{"issue":"5","key":"4729_CR68","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41416-020-01187-8","volume":"124","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Zhao S, Luo L, Xiang Q, Zhu Z, Wang J et al (2021) miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial\u2013mesenchymal transition. Br J Cancer 124(5):982\u2013994","journal-title":"Br J Cancer"},{"issue":"9","key":"4729_CR69","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/cncr.20970","volume":"103","author":"SM Wiseman","year":"2005","unstructured":"Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M et al (2005) Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 103(9):1770\u20131777","journal-title":"Cancer"},{"issue":"33","key":"4729_CR70","doi-asserted-by":"publisher","first-page":"20996","DOI":"10.1074\/jbc.273.33.20996","volume":"273","author":"U Vijapurkar","year":"1998","unstructured":"Vijapurkar U, Cheng K, Koland JG (1998) Mutation of a Shc binding site tyrosine residue in ErbB3\/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase. J Biol Chem 273(33):20996\u201321002","journal-title":"J Biol Chem"},{"issue":"6","key":"4729_CR71","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1600-0463.2008.01024.x","volume":"116","author":"H Nalwoga","year":"2008","unstructured":"Nalwoga H, Arnes JB, Wabinga H, Akslen LA (2008) Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. APMIS Acta Pathol Microbiol Immunol Scand 116(6):515\u2013525","journal-title":"APMIS Acta Pathol Microbiol Immunol Scand"},{"issue":"20","key":"4729_CR72","first-page":"6772","volume":"63","author":"PA Davol","year":"2003","unstructured":"Davol PA, Bagdasaryan R, Elfenbein GJ, Maizel AL, Frackelton AR Jr (2003) Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer. Can Res 63(20):6772\u20136783","journal-title":"Can Res"},{"issue":"20","key":"4729_CR73","doi-asserted-by":"publisher","first-page":"7776","DOI":"10.1158\/0008-5472.CAN-10-2229","volume":"70","author":"J Ursini-Siegel","year":"2010","unstructured":"Ursini-Siegel J, Cory S, Zuo D, Hardy WR, Rexhepaj E, Lam S et al (2010) Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. Can Res 70(20):7776\u20137787","journal-title":"Can Res"},{"issue":"1","key":"4729_CR74","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12032-021-01458-1","volume":"38","author":"NM Ayoub","year":"2021","unstructured":"Ayoub NM, Alkhalifa AE, Ibrahim DR, Alhusban A (2021) Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor. Med Oncol (Northwood, Lond, Engl) 38(1):8","journal-title":"Med Oncol (Northwood, Lond, Engl)"},{"key":"4729_CR75","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/1476-4598-13-185","volume":"13","author":"Y Imura","year":"2014","unstructured":"Imura Y, Yasui H, Outani H, Wakamatsu T, Hamada K, Nakai T et al (2014) Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma. Mol Cancer 13:185","journal-title":"Mol Cancer"},{"issue":"24","key":"4729_CR76","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1200\/JCO.2014.60.7317","volume":"33","author":"G Scagliotti","year":"2015","unstructured":"Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F et al (2015) Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 33(24):2667\u20132674","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"13","key":"4729_CR77","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1158\/0008-5472.CAN-11-3720","volume":"72","author":"L Xu","year":"2012","unstructured":"Xu L, Kikuchi E, Xu C, Ebi H, Ercan D, Cheng KA et al (2012) Combined EGFR\/MET or EGFR\/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Can Res 72(13):3302\u20133311","journal-title":"Can Res"},{"issue":"11","key":"4729_CR78","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1358\/dot.2013.49.11.2020937","volume":"49","author":"K Haddley","year":"2013","unstructured":"Haddley K (2013) Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer. Drugs Today (Barcelona, Spain, 1998) 49(11):701\u2013715","journal-title":"Drugs Today (Barcelona, Spain, 1998)"},{"key":"4729_CR79","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13058-015-0648-2","volume":"17","author":"D Mendes","year":"2015","unstructured":"Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L et al (2015) The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer\u2014a systematic review. Breast Cancer Res 17:140","journal-title":"Breast Cancer Res"},{"key":"4729_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107677","volume":"218","author":"Y Zhang","year":"2021","unstructured":"Zhang Y (2021) The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance. Pharmacol Ther 218:107677","journal-title":"Pharmacol Ther"},{"issue":"14","key":"4729_CR81","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408\u20131417","journal-title":"N Engl J Med"},{"issue":"7","key":"4729_CR82","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","volume":"25","author":"JY Douillard","year":"2014","unstructured":"Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M et al (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol 25(7):1346\u20131355","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"4729_CR83","first-page":"326","volume":"16","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Xiao H, Jin F, Li M, Luo J, Wang G (2018) Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3\/Akt pathway activation. Oncol Lett 16(1):326\u2013334","journal-title":"Oncol Lett"},{"key":"4729_CR84","first-page":"93","volume":"9","author":"MM Chan","year":"2015","unstructured":"Chan MM, Sjoquist KM, Zalcberg JR (2015) Clinical utility of ramucirumab in advanced gastric cancer. Biol Targets Therapy 9:93\u2013105","journal-title":"Biol Targets Therapy"},{"issue":"9911","key":"4729_CR85","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (Lond, Engl) 383(9911):31\u201339","journal-title":"Lancet (Lond, Engl)"},{"issue":"2","key":"4729_CR86","doi-asserted-by":"publisher","first-page":"824","DOI":"10.7150\/thno.49600","volume":"11","author":"Q Zheng","year":"2021","unstructured":"Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S et al (2021) A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics 11(2):824\u2013840","journal-title":"Theranostics"},{"issue":"1","key":"4729_CR87","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12929-022-00788-0","volume":"29","author":"YL Lai","year":"2022","unstructured":"Lai YL, Wang KH, Hsieh HP, Yen WC (2022) Novel FLT3\/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma. J Biomed Sci 29(1):5","journal-title":"J Biomed Sci"},{"issue":"7","key":"4729_CR88","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/cam4.1121","volume":"6","author":"CH Chang","year":"2017","unstructured":"Chang CH, Lee CH, Ko JC, Chang LY, Lee MC, Wang JY et al (2017) Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan. Cancer Med 6(7):1563\u20131572","journal-title":"Cancer Med"},{"issue":"5","key":"4729_CR89","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40273-021-01022-9","volume":"39","author":"YJ Kim","year":"2021","unstructured":"Kim YJ, Oremus M, Chen HH, McFarlane T, Fearon D, Horton S (2021) Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as first-line treatments for EGFR mutation-positive non-small-cell lung cancer in Ontario, Canada. Pharmacoeconomics 39(5):537\u2013548","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"4729_CR90","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1097\/CAD.0000000000001148","volume":"33","author":"LD Zhang","year":"2022","unstructured":"Zhang LD, Gao H, Qin SM, Zeng Q, Chen QF (2022) Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18\u201325 kinase domain duplication: report of two cases. Anticancer Drugs 33(1):e486\u2013e490","journal-title":"Anticancer Drugs"},{"issue":"7","key":"4729_CR91","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2169\/internalmedicine.5463-20","volume":"60","author":"Y Yoshimatsu","year":"2021","unstructured":"Yoshimatsu Y, Ebi N, Ooi R, Sueyasu T, Nishizawa S, Munechika M et al (2021) Osimertinib for lung squamous cell carcinoma: a case report and literature review. Intern Med (Tokyo, Jpn) 60(7):1067\u20131071","journal-title":"Intern Med (Tokyo, Jpn)"},{"issue":"3","key":"4729_CR92","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5603\/ARM.2020.0130","volume":"88","author":"M Knetki-Wr\u00f3blewska","year":"2020","unstructured":"Knetki-Wr\u00f3blewska M, Kowalski DM, Czy\u017cewicz G, Bryl M, Wrona A, Dziadziuszko R et al (2020) Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice\u2014the Expanded Drug Access Program in Poland. Adv Respir Med 88(3):189\u2013196","journal-title":"Adv Respir Med"},{"issue":"1","key":"4729_CR93","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00280-021-04369-0","volume":"89","author":"SK Padda","year":"2022","unstructured":"Padda SK, Reckamp KL, Koczywas M, Neal JW, Kawashima J, Kong S et al (2022) A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemother Pharmacol 89(1):105\u2013115","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"4729_CR94","first-page":"1045","volume":"46","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang Y, Niu W, Ge X, Li X, Fan F et al (2021) Effect of almonertinib on the proliferation, invasion, and migration in non-small cell lung cancer cells. Zhong nan da xue xue bao Yi xue ban J Central South Univ Med Sci 46(10):1045\u20131053","journal-title":"Zhong nan da xue xue bao Yi xue ban J Central South Univ Med Sci"},{"issue":"Suppl 2","key":"4729_CR95","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.21037\/tlcr.2018.03.19","volume":"7","author":"V Gregorc","year":"2018","unstructured":"Gregorc V, Lazzari C, Karachaliou N, Rosell R, Santarpia M (2018) Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. Transl Lung Cancer Res 7(Suppl 2):S165\u2013S170","journal-title":"Transl Lung Cancer Res"},{"key":"4729_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103564","volume":"169","author":"A Awada","year":"2022","unstructured":"Awada A, Berghmans T, Clement PM, Cuppens K, De Wilde B, Machiels JP et al (2022) Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib. Crit Rev Oncol Hematol 169:103564","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"4729_CR97","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1358\/dot.2011.47.5.1584110","volume":"47","author":"A Awada","year":"2011","unstructured":"Awada A, Saliba W, Bozovic-Spasojevic I (2011) Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer. Drugs Today (Barcelona, Spain, 1998) 47(5):335\u2013345","journal-title":"Drugs Today (Barcelona, Spain, 1998)"},{"issue":"7","key":"4729_CR98","first-page":"626","volume":"23","author":"B Ai","year":"2020","unstructured":"Ai B, Yang Y (2020) [Progress of bevacizumab in the front-line treatment of advanced non-small cell lung cancer]. Zhongguo fei ai za zhi Chinese J Lung Cancer 23(7):626\u2013630","journal-title":"Zhongguo fei ai za zhi Chinese J Lung Cancer"},{"issue":"1","key":"4729_CR99","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ijc.32638","volume":"146","author":"ME Nome","year":"2020","unstructured":"Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giske\u00f8deg\u00e5rd GF et al (2020) Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers. Int J Cancer 146(1):223\u2013235","journal-title":"Int J Cancer"},{"issue":"1","key":"4729_CR100","doi-asserted-by":"publisher","first-page":"93","DOI":"10.7150\/thno.46593","volume":"11","author":"Z Yu","year":"2021","unstructured":"Yu Z, Du J, Hui H, Kan S, Huo T, Zhao K et al (2021) LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia. Theranostics 11(1):93\u2013106","journal-title":"Theranostics"},{"key":"4729_CR101","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/OTT.S127679","volume":"11","author":"E Weisberg","year":"2018","unstructured":"Weisberg E, Sattler M, Manley PW, Griffin JD (2018) Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy. Onco Targets Ther 11:175\u2013182","journal-title":"Onco Targets Ther"},{"issue":"2","key":"4729_CR102","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/cancers12020512","volume":"12","author":"M Krayem","year":"2020","unstructured":"Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L et al (2020) Kinome profiling to predict sensitivity to MAPK inhibition in melanoma and to provide new insights into intrinsic and acquired mechanism of resistance. Cancers 12(2):512","journal-title":"Cancers"},{"issue":"3","key":"4729_CR103","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/2159-8290.CD-14-0295","volume":"5","author":"B Miao","year":"2015","unstructured":"Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG et al (2015) EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov 5(3):274\u2013287","journal-title":"Cancer Discov"},{"issue":"7","key":"4729_CR104","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1038\/s41418-019-0488-1","volume":"27","author":"I Das","year":"2020","unstructured":"Das I, Gad H, Br\u00e4utigam L, Pudelko L, Tuominen R, H\u00f6iom V et al (2020) AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma. Cell Death Differ 27(7):2081\u20132098","journal-title":"Cell Death Differ"},{"issue":"7","key":"4729_CR105","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1158\/0008-5472.CAN-20-0434","volume":"81","author":"J Boshuizen","year":"2021","unstructured":"Boshuizen J, Pencheva N, Krijgsman O, Altimari DD, Castro PG, de Bruijn B et al (2021) Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade. Can Res 81(7):1775\u20131787","journal-title":"Can Res"},{"issue":"4","key":"4729_CR106","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/1759-7714.14299","volume":"13","author":"K Zhou","year":"2022","unstructured":"Zhou K, Cai X, Wang X, Lan X, Zhang X (2022) Efficacy and safety of WBRT+EGFR-TKI versus WBRT only in the treatment of NSCLC patients with brain metastasis: an updated meta-analysis. Thoracic Cancer 13(4):563\u2013570","journal-title":"Thoracic Cancer"},{"issue":"1","key":"4729_CR107","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-018-0800-6","volume":"17","author":"HY Tan","year":"2018","unstructured":"Tan HY, Wang N, Lam W, Guo W, Feng Y, Cheng YC (2018) Targeting tumour microenvironment by tyrosine kinase inhibitor. Mol Cancer 17(1):43","journal-title":"Mol Cancer"},{"issue":"8","key":"4729_CR108","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41577-019-0271-z","volume":"20","author":"H Garner","year":"2020","unstructured":"Garner H, de Visser KE (2020) Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol 20(8):483\u2013497","journal-title":"Nat Rev Immunol"},{"key":"4729_CR109","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3389\/fimmu.2020.00940","volume":"11","author":"A Labani-Motlagh","year":"2020","unstructured":"Labani-Motlagh A, Ashja-Mahdavi M, Loskog A (2020) The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses. Front Immunol 11:940","journal-title":"Front Immunol"},{"issue":"9","key":"4729_CR110","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S1470-2045(21)00387-9","volume":"22","author":"N Gaspar","year":"2021","unstructured":"Gaspar N, Venkatramani R, Hecker-Nolting S, Melcon SG, Locatelli F, Bautista F et al (2021) Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1\/2 study. Lancet Oncol 22(9):1312\u20131321","journal-title":"Lancet Oncol"},{"issue":"3","key":"4729_CR111","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","volume":"21","author":"A Italiano","year":"2020","unstructured":"Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E et al (2020) Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol 21(3):446\u2013455","journal-title":"Lancet Oncol"},{"key":"4729_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.811687","volume":"12","author":"L Tang","year":"2022","unstructured":"Tang L, Niu X, Wang Z, Cai Q, Tu C, Fan Z et al (2022) Anlotinib for recurrent or metastatic primary malignant bone tumor: a multicenter, single-arm trial. Front Oncol 12:811687","journal-title":"Front Oncol"},{"issue":"7647","key":"4729_CR113","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nature21676","volume":"543","author":"X Lu","year":"2017","unstructured":"Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P et al (2017) Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543(7647):728\u2013732","journal-title":"Nature"},{"issue":"12","key":"4729_CR114","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1158\/1535-7163.MCT-18-1399","volume":"18","author":"P Bergerot","year":"2019","unstructured":"Bergerot P, Lamb P, Wang E, Pal SK (2019) Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence. Mol Cancer Ther 18(12):2185\u20132193","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"4729_CR115","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-16-0778","volume":"7","author":"A Patnaik","year":"2017","unstructured":"Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP et al (2017) Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity. Cancer Discov 7(7):750\u2013765","journal-title":"Cancer Discov"},{"key":"4729_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.689727","volume":"9","author":"Y Fu","year":"2021","unstructured":"Fu Y, Peng Y, Zhao S, Mou J, Zeng L, Jiang X et al (2021) Combination foretinib and anti-PD-1 antibody immunotherapy for colorectal carcinoma. Front Cell Dev Biol 9:689727","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"4729_CR117","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/nm.3388","volume":"19","author":"CR Chong","year":"2013","unstructured":"Chong CR, J\u00e4nne PA (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19(11):1389\u20131400","journal-title":"Nat Med"},{"issue":"7","key":"4729_CR118","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/cancers13071521","volume":"13","author":"M Wium","year":"2021","unstructured":"Wium M, Ajayi-Smith AF, Paccez JD, Zerbini LF (2021) The role of the receptor tyrosine kinase Axl in carcinogenesis and development of therapeutic resistance: an overview of molecular mechanisms and future applications. Cancers 13(7):1521","journal-title":"Cancers"},{"key":"4729_CR119","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/bs.acr.2018.02.003","volume":"138","author":"SA Rosenzweig","year":"2018","unstructured":"Rosenzweig SA (2018) Acquired resistance to drugs targeting tyrosine kinases. Adv Cancer Res 138:71\u201398","journal-title":"Adv Cancer Res"},{"issue":"3","key":"4729_CR120","doi-asserted-by":"publisher","first-page":"339","DOI":"10.15171\/apb.2017.041","volume":"7","author":"B Mansoori","year":"2017","unstructured":"Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B (2017) The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull 7(3):339\u2013348","journal-title":"Adv Pharm Bull"},{"issue":"2","key":"4729_CR121","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1021\/acs.jmedchem.1c00876","volume":"65","author":"M Shaikh","year":"2022","unstructured":"Shaikh M, Shinde Y, Pawara R, Noolvi M, Surana S, Ahmad I et al (2022) Emerging approaches to overcome acquired drug resistance obstacles to osimertinib in non-small-cell lung cancer. J Med Chem 65(2):1008\u20131046","journal-title":"J Med Chem"},{"issue":"7","key":"4729_CR122","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7):2640\u20132653","journal-title":"Blood"},{"issue":"2","key":"4729_CR123","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3892\/mco.2021.2463","volume":"16","author":"C He","year":"2022","unstructured":"He C, Wang Y (2022) Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: a case report. Mol Clin Oncol 16(2):30","journal-title":"Mol Clin Oncol"},{"key":"4729_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.630256","volume":"11","author":"W Xiu","year":"2021","unstructured":"Xiu W, Zhang Q, Yu M, Huang Y, Huang M (2021) Case report: outcome of osimertinib treatment in lung adenocarcinoma patients with acquired KRAS mutations. Front Oncol 11:630256","journal-title":"Front Oncol"},{"issue":"1","key":"4729_CR125","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/cas.15177","volume":"113","author":"S Liu","year":"2022","unstructured":"Liu S, Jiang Z, Xiao P, Li X, Chen Y, Tang H et al (2022) Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p\/IGF1R axis in lung adenocarcinoma cells. Cancer Sci 113(1):79\u201390","journal-title":"Cancer Sci"},{"issue":"1","key":"4729_CR126","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1097\/CAD.0000000000001242","volume":"33","author":"F Qu","year":"2022","unstructured":"Qu F, Zhou Y, Yu W (2022) A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance. Anticancer Drugs 33(1):e76\u2013e83","journal-title":"Anticancer Drugs"},{"issue":"2","key":"4729_CR127","doi-asserted-by":"publisher","first-page":"709","DOI":"10.21873\/anticanres.15529","volume":"42","author":"N Takano","year":"2022","unstructured":"Takano N, Seike M, Sugano T, Matsuda K, Hisakane K, Yoshikawa A et al (2022) A novel molecular target in EGFR-mutant lung cancer treated with the combination of osimertinib and pemetrexed. Anticancer Res 42(2):709\u2013722","journal-title":"Anticancer Res"},{"issue":"9","key":"4729_CR128","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1111\/cas.15036","volume":"112","author":"R Yiming","year":"2021","unstructured":"Yiming R, Takeuchi Y, Nishimura T, Li M, Wang Y, Meguro-Horike M et al (2021) MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma. Cancer Sci 112(9):3810\u20133821","journal-title":"Cancer Sci"},{"issue":"2","key":"4729_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100079","volume":"6","author":"T Cascone","year":"2021","unstructured":"Cascone T, Sacks RL, Subbiah IM, Drobnitzky N, Piha-Paul SA, Hong DS et al (2021) Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. ESMO Open 6(2):100079","journal-title":"ESMO Open"},{"issue":"22","key":"4729_CR130","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 27(22):3584\u20133590","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"20","key":"4729_CR131","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol Off J Am Soc Clin Oncol 27(20):3312\u20133318","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"4729_CR132","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JM Ebos","year":"2009","unstructured":"Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3):232\u2013239","journal-title":"Cancer Cell"},{"issue":"16","key":"4729_CR133","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-12-1557","volume":"19","author":"Y Piao","year":"2013","unstructured":"Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF (2013) Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res Off J Am Assoc Cancer Res 19(16):4392\u20134403","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"4729_CR134","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.molmed.2017.01.002","volume":"23","author":"T Simon","year":"2017","unstructured":"Simon T, Gagliano T, Giamas G (2017) Direct effects of anti-angiogenic therapies on tumor cells: VEGF signaling. Trends Mol Med 23(3):282\u2013292","journal-title":"Trends Mol Med"},{"issue":"8","key":"4729_CR135","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809266","volume":"11","author":"I Uribesalgo","year":"2019","unstructured":"Uribesalgo I, Hoffmann D, Zhang Y, Kavirayani A, Lazovic J, Berta J et al (2019) Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy. EMBO Mol Med 11(8):e9266","journal-title":"EMBO Mol Med"},{"issue":"2","key":"4729_CR136","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cmet.2014.05.022","volume":"20","author":"NE Sounni","year":"2014","unstructured":"Sounni NE, Cimino J, Blacher S, Primac I, Truong A, Mazzucchelli G et al (2014) Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab 20(2):280\u2013294","journal-title":"Cell Metab"},{"issue":"6","key":"4729_CR137","doi-asserted-by":"publisher","first-page":"606","DOI":"10.2174\/1389450122666210824144907","volume":"23","author":"A Srivastava","year":"2022","unstructured":"Srivastava A, Srivastava P, Mathur S, Abbas S, Rai N, Tiwari S et al (2022) Lipid metabolism and mitochondria: cross talk in cancer. Curr Drug Targets 23(6):606\u2013627","journal-title":"Curr Drug Targets"},{"issue":"7","key":"4729_CR138","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/cam4.711","volume":"5","author":"H Wang","year":"2016","unstructured":"Wang H, Xi Q, Wu G (2016) Fatty acid synthase regulates invasion and metastasis of colorectal cancer via Wnt signaling pathway. Cancer Med 5(7):1599\u20131606","journal-title":"Cancer Med"},{"issue":"1","key":"4729_CR139","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147717","volume":"11","author":"Y Yasumoto","year":"2016","unstructured":"Yasumoto Y, Miyazaki H, Vaidyan LK, Kagawa Y, Ebrahimi M, Yamamoto Y et al (2016) Inhibition of fatty acid synthase decreases expression of stemness markers in glioma stem cells. PLoS ONE 11(1):e0147717","journal-title":"PLoS ONE"},{"issue":"29","key":"4729_CR140","doi-asserted-by":"publisher","first-page":"8290","DOI":"10.1073\/pnas.1601571113","volume":"113","author":"I Ahmad","year":"2016","unstructured":"Ahmad I, Mui E, Galbraith L, Patel R, Tan EH, Salji M et al (2016) Sleeping beauty screen reveals Pparg activation in metastatic prostate cancer. Proc Natl Acad Sci USA 113(29):8290\u20138295","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"4729_CR141","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12931-021-01719-7","volume":"22","author":"S Wang","year":"2021","unstructured":"Wang S, Liu C, Lei Q, Wu Z, Miao X, Zhu D et al (2021) Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells. Respir Res 22(1):146","journal-title":"Respir Res"},{"issue":"3","key":"4729_CR142","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/CAD.0000000000001142","volume":"33","author":"H Satoh","year":"2022","unstructured":"Satoh H, Kagohashi K (2022) Response to erlotinib and bevacizumab combination therapy after acquired resistance to osimertinib in patients with non-small cell lung cancer. Anticancer Drugs 33(3):320\u2013322","journal-title":"Anticancer Drugs"},{"issue":"2","key":"4729_CR143","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3390\/ijms23020982","volume":"23","author":"L Scherschinski","year":"2022","unstructured":"Scherschinski L, Prem M, Kremenetskaia I, Tinhofer I, Vajkoczy P, Karbe AG et al (2022) Regulation of the receptor tyrosine kinase AXL in response to therapy and its role in therapy resistance in glioblastoma. Int J Mol Sci 23(2):982","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4729_CR144","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003831","volume":"10","author":"L Xia","year":"2022","unstructured":"Xia L, Peng J, Lou G, Pan M, Zhou Q, Hu W et al (2022) Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. J Immunother Cancer. 10(1):e003831","journal-title":"J Immunother Cancer."},{"issue":"1","key":"4729_CR145","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/1078-0432.CCR-20-2278","volume":"27","author":"EY Rosen","year":"2021","unstructured":"Rosen EY, Johnson ML, Clifford SE, Somwar R, Kherani JF, Son J et al (2021) Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib. Clin Cancer Res Off J Am Assoc Cancer Res 27(1):34\u201342","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"10","key":"4729_CR146","first-page":"944","volume":"20","author":"H Abe","year":"2013","unstructured":"Abe H, Kamai T (2013) Recent advances in the treatment of metastatic renal cell carcinoma. Int J Urol Off J Jpn Urol Assoc 20(10):944\u2013955","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"issue":"4","key":"4729_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101128","volume":"297","author":"AE Yesilkanal","year":"2021","unstructured":"Yesilkanal AE, Johnson GL, Ramos AF, Rosner MR (2021) New strategies for targeting kinase networks in cancer. J Biol Chem 297(4):101128","journal-title":"J Biol Chem"},{"issue":"24","key":"4729_CR148","doi-asserted-by":"publisher","first-page":"6150","DOI":"10.3390\/cancers14246150","volume":"14","author":"D Sinha","year":"2022","unstructured":"Sinha D, Moseley P, Lu X, Wright Q, Gabrielli B, Frazer IH et al (2022) Repurposing of commercially existing molecular target therapies to boost the clinical efficacy of immune checkpoint blockade. Cancers 14(24):6150","journal-title":"Cancers"},{"issue":"3","key":"4729_CR149","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/cancers12030731","volume":"12","author":"C Pottier","year":"2020","unstructured":"Pottier C, Fresnais M, Gilon M, J\u00e9rusalem G, Longuesp\u00e9e R, Sounni NE (2020) Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers 12(3):731","journal-title":"Cancers"},{"key":"4729_CR150","first-page":"98","volume":"2017","author":"D Jones","year":"2018","unstructured":"Jones D, Bopaiah J, Alghamedy F, Jacobs N, Weiss HL, de Jong WA et al (2018) Polypharmacology within the full kinome: a machine learning approach. AMIA Jt Summits Transl Sci Proc 2017:98\u2013107","journal-title":"AMIA Jt Summits Transl Sci Proc"},{"issue":"9","key":"4729_CR151","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41587-019-0224-x","volume":"37","author":"A Zhavoronkov","year":"2019","unstructured":"Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV et al (2019) Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol 37(9):1038\u20131040","journal-title":"Nat Biotechnol"},{"issue":"7","key":"4729_CR152","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1021\/jm400099d","volume":"56","author":"B Desai","year":"2013","unstructured":"Desai B, Dixon K, Farrant E, Feng Q, Gibson KR, van Hoorn WP et al (2013) Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform. J Med Chem 56(7):3033\u20133047","journal-title":"J Med Chem"},{"issue":"1","key":"4729_CR153","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1038\/s41467-019-10685-0","volume":"10","author":"M Benz","year":"2019","unstructured":"Benz M, Molla MR, B\u00f6ser A, Rosenfeld A, Levkin PA (2019) Marrying chemistry with biology by combining on-chip solution-based combinatorial synthesis and cellular screening. Nat Commun 10(1):2879","journal-title":"Nat Commun"},{"issue":"2","key":"4729_CR154","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41568-018-0104-6","volume":"19","author":"A Sontheimer-Phelps","year":"2019","unstructured":"Sontheimer-Phelps A, Hassell BA, Ingber DE (2019) Modelling cancer in microfluidic human organs-on-chips. Nat Rev Cancer 19(2):65\u201381","journal-title":"Nat Rev Cancer"},{"key":"4729_CR155","doi-asserted-by":"crossref","unstructured":"Linifanib (2010) Drugs in R&D. 10(2):111\u2013122","DOI":"10.2165\/11584520-000000000-00000"},{"issue":"4\u20135","key":"4729_CR156","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/07357907.2019.1601209","volume":"37","author":"Y Adachi","year":"2019","unstructured":"Adachi Y, Matsuki M, Watanabe H, Takase K, Kodama K, Matsui J et al (2019) Antitumor and antiangiogenic activities of lenvatinib in mouse xenograft models of vascular endothelial growth factor-induced hypervascular human hepatocellular carcinoma. Cancer Invest 37(4\u20135):185\u2013198","journal-title":"Cancer Invest"},{"issue":"1","key":"4729_CR157","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40360-018-0264-8","volume":"19","author":"MJ M\u00e9ndez-Vidal","year":"2018","unstructured":"M\u00e9ndez-Vidal MJ, Molina \u00c1, Anido U, Chirivella I, Etxaniz O, Fern\u00e1ndez-Parra E et al (2018) Pazopanib: evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC Pharmacol Toxicol 19(1):77","journal-title":"BMC Pharmacol Toxicol"},{"issue":"15 suppl","key":"4729_CR158","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1200\/jco.2008.26.15_suppl.5046","volume":"26","author":"T Hutson","year":"2008","unstructured":"Hutson T, Davis I, Machiels J, De Souza P, Baker K, Bordogna W et al (2008) Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 26(15 suppl):5046","journal-title":"J Clin Oncol"},{"issue":"11","key":"4729_CR159","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1158\/0008-5472.CAN-17-3386","volume":"78","author":"R Adelaiye-Ogala","year":"2018","unstructured":"Adelaiye-Ogala R, Damayanti NP, Orillion AR, Arisa S, Chintala S, Titus MA et al (2018) Therapeutic targeting of sunitinib-induced AR phosphorylation in renal cell carcinoma. Can Res 78(11):2886\u20132896","journal-title":"Can Res"},{"issue":"1","key":"4729_CR160","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/s13256-021-03037-4","volume":"15","author":"MN Abbas","year":"2021","unstructured":"Abbas MN, Tan WS, Kichenadasse G (2021) Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report. J Med Case Rep 15(1):481","journal-title":"J Med Case Rep"},{"key":"4729_CR161","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/bs.podrm.2018.11.003","volume-title":"Profiles of drug substances, excipients, and related methodology","author":"AA Abdelgalil","year":"2019","unstructured":"Abdelgalil AA, Alkahtani HM, Al-Jenoobi FI (2019) Sorafenib. Profiles of drug substances, excipients, and related methodology, vol 44. Elsevier, Amsterdam, pp 239\u2013266"},{"issue":"12","key":"4729_CR162","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","volume":"25","author":"BH Durham","year":"2019","unstructured":"Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S et al (2019) Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med 25(12):1839\u20131842","journal-title":"Nat Med"},{"issue":"2","key":"4729_CR163","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/1078-0432.CCR-21-2007","volume":"28","author":"WD Tap","year":"2022","unstructured":"Tap WD, Singh AS, Anthony SP, Sterba M, Zhang C, Healey JH et al (2022) Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT. Clin Cancer Res Off J Am Assoc Cancer Res 28(2):298\u2013307","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"4729_CR164","doi-asserted-by":"publisher","first-page":"6205","DOI":"10.1007\/s11033-019-05059-0","volume":"46","author":"A Asgari","year":"2019","unstructured":"Asgari A, Sharifzadeh S, Ghaderi A, Hosseini A, Ramezani A (2019) In vitro cytotoxic effect of trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells. Mol Biol Rep 46(6):6205\u20136213","journal-title":"Mol Biol Rep"},{"key":"4729_CR165","first-page":"147","volume":"7","author":"K Feldinger","year":"2015","unstructured":"Feldinger K, Kong A (2015) Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer 7:147\u2013162","journal-title":"Breast Cancer"},{"issue":"3","key":"4729_CR166","first-page":"2729","volume":"17","author":"Y Ogoshi","year":"2019","unstructured":"Ogoshi Y, Shien K, Yoshioka T, Torigoe H, Sato H, Sakaguchi M et al (2019) Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations. Oncol Lett 17(3):2729\u20132736","journal-title":"Oncol Lett"},{"issue":"9","key":"4729_CR167","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2174\/1568009614666141111104643","volume":"14","author":"D Subramaniam","year":"2015","unstructured":"Subramaniam D, He AR, Hwang J, Deeken J, Pishvaian M, Hartley ML et al (2015) Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer. Curr Cancer Drug Targets 14(9):775\u2013793","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"4729_CR168","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.canlet.2016.08.026","volume":"382","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Zhang J, Liu C, Du S, Feng L, Luan X et al (2016) Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells. Cancer Lett 382(2):176\u2013185","journal-title":"Cancer Lett"},{"issue":"6","key":"4729_CR169","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/cbdd.13974","volume":"100","author":"MN Abdullah","year":"2021","unstructured":"Abdullah MN, Ali Y, Abd HS (2021) Insights into the structure and drug design of benzimidazole derivatives targeting the epidermal growth factor receptor (EGFR). Chem Biol Drug Des 100(6):921\u2013934","journal-title":"Chem Biol Drug Des"},{"issue":"4","key":"4729_CR170","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3390\/molecules25040770","volume":"25","author":"HT Abdel-Mohsen","year":"2020","unstructured":"Abdel-Mohsen HT, Abdullaziz MA, Kerdawy AME, Ragab FAF, Flanagan KJ, Mahmoud AEE et al (2020) Targeting receptor tyrosine kinase VEGFR-2 in hepatocellular cancer: rational design, synthesis and biological evaluation of 1,2-disubstituted benzimidazoles. Molecules (Basel, Switzerland). 25(4):770","journal-title":"Molecules (Basel, Switzerland)."},{"key":"4729_CR171","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.672500","volume":"11","author":"S Bauer","year":"2021","unstructured":"Bauer S, George S, von Mehren M, Heinrich MC (2021) Early and next-generation KIT\/PDGFRA kinase inhibitors and the future of treatment for advanced gastrointestinal stromal tumor. Front Oncol 11:672500","journal-title":"Front Oncol"},{"issue":"3","key":"4729_CR172","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1536\/ihj.19-556","volume":"61","author":"S Yoshikawa","year":"2020","unstructured":"Yoshikawa S, Hara T, Suzuki M, Fujioka M, Taniguchi Y, Hirata KI (2020) Imatinib dramatically improved pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy (PTTM) associated with metastatic breast cancer. Int Heart J 61(3):624\u2013628","journal-title":"Int Heart J"},{"key":"4729_CR173","doi-asserted-by":"publisher","first-page":"153303461774941","DOI":"10.1177\/1533034617749418","volume":"17","author":"M Guan","year":"2018","unstructured":"Guan M, Tong Y, Guan M, Liu X, Wang M, Niu R et al (2018) Lapatinib inhibits breast cancer cell proliferation by influencing PKM2 expression. Technol Cancer Res Treat 17:1533034617749418","journal-title":"Technol Cancer Res Treat"},{"issue":"6","key":"4729_CR174","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00280-015-2855-z","volume":"76","author":"Z Wu","year":"2015","unstructured":"Wu Z, Gabrielson A, Hwang JJ, Pishvaian MJ, Weiner LM, Zhuang T et al (2015) Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Cancer Chemother Pharmacol 76(6):1309\u20131314","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"4729_CR175","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1158\/1535-7163.MCT-15-0565","volume":"15","author":"I Kj\u00e6r","year":"2016","unstructured":"Kj\u00e6r I, Lindsted T, Fr\u00f6hlich C, Olsen JV, Horak ID, Kragh M et al (2016) Cetuximab resistance in squamous carcinomas of the upper aerodigestive tract is driven by receptor tyrosine kinase plasticity: potential for mAb mixtures. Mol Cancer Ther 15(7):1614\u20131626","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4729_CR176","first-page":"6","volume":"11","author":"DR Goulet","year":"2022","unstructured":"Goulet DR, Chatterjee S, Lee WP, Waight AB, Zhu Y, Mak AN (2022) Engineering an enhanced EGFR engager: humanization of cetuximab for improved developability. Antibodies (Basel, Switzerland) 11(1):6","journal-title":"Antibodies (Basel, Switzerland)"},{"key":"4729_CR177","volume-title":"Lenvatinib. StatPearls","author":"IS Padda","year":"2022","unstructured":"Padda IS, Parmar M (2022) Lenvatinib. StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"issue":"1","key":"4729_CR178","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.annonc.2020.09.021","volume":"32","author":"L Albiges","year":"2021","unstructured":"Albiges L, Barth\u00e9l\u00e9my P, Gross-Goupil M, Negrier S, Needle MN, Escudier B (2021) TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma. Ann Oncol Off J Eur Soc Med Oncol 32(1):97\u2013102","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"13","key":"4729_CR179","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.3390\/cancers13133288","volume":"13","author":"T Alqahtani","year":"2021","unstructured":"Alqahtani T, Alswied A, Sun D (2021) Selective antitumor activity of datelliptium toward medullary thyroid carcinoma by downregulating RET transcriptional activity. Cancers 13(13):3288","journal-title":"Cancers"},{"issue":"6","key":"4729_CR180","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00280-021-04242-0","volume":"87","author":"NK Gortany","year":"2021","unstructured":"Gortany NK, Panahi G, Ghafari H, Shekari M, Ghazi-Khansari M (2021) Foretinib induces G2\/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition. Cancer Chemother Pharmacol 87(6):827\u2013842","journal-title":"Cancer Chemother Pharmacol"},{"key":"4729_CR181","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2147\/OTT.S226951","volume":"13","author":"SH Sohn","year":"2020","unstructured":"Sohn SH, Kim B, Sul HJ, Choi BY, Kim HS, Zang DY (2020) Foretinib inhibits cancer stemness and gastric cancer cell proliferation by decreasing CD44 and c-MET signaling. Onco Targets Ther 13:1027\u20131035","journal-title":"Onco Targets Ther"},{"key":"4729_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109747","volume":"351","author":"S Jiang","year":"2022","unstructured":"Jiang S, Jiang T, Huang H, Chen X, Li L, Wang Z et al (2022) CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway. Chem Biol Interact 351:109747","journal-title":"Chem Biol Interact"},{"issue":"1","key":"4729_CR183","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1186\/s12885-021-08590-1","volume":"21","author":"W Yu","year":"2021","unstructured":"Yu W, Ye F, Yuan X, Ma Y, Mao C, Li X et al (2021) A phase I\/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer. BMC Cancer 21(1):877","journal-title":"BMC Cancer"},{"issue":"2","key":"4729_CR184","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10637-020-01010-4","volume":"39","author":"JJ Yang","year":"2021","unstructured":"Yang JJ, Fang J, Shu YQ, Chang JH, Chen GY, He JX et al (2021) A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. Invest New Drugs 39(2):477\u2013487","journal-title":"Invest New Drugs"},{"issue":"4","key":"4729_CR185","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.21037\/tlcr-21-192","volume":"10","author":"T Li","year":"2021","unstructured":"Li T, Qian Y, Zhang C, Uchino J, Provencio M, Wang Y et al (2021) Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo. Transl Lung Cancer Res 10(4):1873\u20131888","journal-title":"Transl Lung Cancer Res"},{"issue":"10","key":"4729_CR186","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2217\/fon-2021-1096","volume":"18","author":"N Agarwal","year":"2022","unstructured":"Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS et al (2022) A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol (Lond, Engl). 18(10):1185\u20131198","journal-title":"Future Oncol (Lond, Engl)."},{"issue":"7","key":"4729_CR187","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41401-020-00546-8","volume":"42","author":"M Tian","year":"2021","unstructured":"Tian M, Chen XS, Li LY, Wu HZ, Zeng D, Wang XL et al (2021) Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis. Acta Pharmacol Sin 42(7):1180\u20131189","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"4729_CR188","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.21873\/anticanres.15237","volume":"41","author":"S Suzuki","year":"2021","unstructured":"Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Seino S, Sugai A et al (2021) Lurasidone sensitizes cancer cells to osimertinib by inducing autophagy and reduction of survivin. Anticancer Res 41(9):4321\u20134331","journal-title":"Anticancer Res"},{"key":"4729_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105392","volume":"164","author":"W Zhou","year":"2021","unstructured":"Zhou W, Gao Y, Tong Y, Wu Q, Zhou Y, Li Y (2021) Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma. Pharmacol Res 164:105392","journal-title":"Pharmacol Res"},{"issue":"2","key":"4729_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112940","volume":"409","author":"N Nakagawa","year":"2021","unstructured":"Nakagawa N, Miyake N, Ochi N, Yamane H, Takeyama M, Nagasaki Y et al (2021) Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells. Exp Cell Res 409(2):112940","journal-title":"Exp Cell Res"},{"issue":"3","key":"4729_CR191","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000514420","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M et al (2021) Avelumab in combination with axitinib as first-line treatment in patients with advanced hepatocellular carcinoma: results from the phase 1b VEGF liver 100 trial. Liver Cancer 10(3):249\u2013259","journal-title":"Liver Cancer"},{"issue":"5","key":"4729_CR192","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.21037\/apm-20-1363","volume":"9","author":"W Zhu","year":"2020","unstructured":"Zhu W, Wu J, Cui M, Zhang L (2020) Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab. Ann Palliat Med 9(5):3684\u20133689","journal-title":"Ann Palliat Med"},{"issue":"10","key":"4729_CR193","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1158\/1078-0432.CCR-17-1623","volume":"24","author":"A Nishiyama","year":"2018","unstructured":"Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K et al (2018) Foretinib overcomes entrectinib resistance associated with the NTRK1 G667C mutation in NTRK1 fusion-positive tumor cells in a brain metastasis model. Clin Cancer Res Off J Am Assoc Cancer Res 24(10):2357\u20132369","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-023-04729-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-023-04729-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-023-04729-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T06:21:56Z","timestamp":1681712516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-023-04729-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":193,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["4729"],"URL":"https:\/\/doi.org\/10.1007\/s00018-023-04729-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2251865\/v1","asserted-by":"object"}]},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"assertion":[{"value":"8 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MRH declares the following potential conflicts of interest. Scientific Advisory Boards: Transdermal Cap Inc, Cleveland, OH; Hologenix Inc. Santa Monica, CA; Vielight, Toronto, Canada; JOOVV Inc, Minneapolis-St. Paul MN; Sunlighten, Kansas City, MO; Consulting; USHIO Corp, Japan; Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany; Klox Asia, Guangzhou, China. Stockholding: Niraxx Light Therapeutics, Inc, Irvine CA; JelikaLite Corp, New York NY. The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"104"}}